Archived Webinar: An Introduction to the Pathogenesis of HIV Infection and Core Principles of Treatment

Assessment of Needs

The IAS–USA offers this introductory activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. This 2-part webinar is designed for HIV or infectious disease fellows, residents, and practitioners who are new to the field of HIV research and management. It will describe the core principles of HIV management, including epidemiology, mechanisms of action of existing drugs, initial antiretroviral regimens, and drug resistance. This webinar will also be useful to experienced clinicians who seek a review of these core principles.

Learning Objectives

Upon completion of this webinar, learners will be able to:

• List key epidemiologic features of the HIV in the United States
• Summarize the key steps in the HIV life cycle
• Describe the mechanism of action of major classes of antiretroviral medications
• Select antiretroviral therapy in patients who are:
  • Starting initial therapy
  • Persistently low-level viremic
  • Pregnant
  • Older

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research.

This activity is also relevant for registered nurses, PharmDs, and other health professionals.

Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.

Conflicts of Interest

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, Merck, Proteus, and ViiV Healthcare. He has served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck, and ViiV Healthcare. (Updated 05/24/18)

Dr Spach has no relevant financial affiliations to disclose. He does not receive any honoraria for the activity. (Updated 5/29/18)